Skip to main content

Recurrent Vulvovaginal Candidiasis

5
Pipeline Programs
4
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
360%
Vaccine
240%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

Mycovia Pharmaceuticals
VIVJOAApproved
oteseconazole
Mycovia Pharmaceuticals
Azole Antifungal [EPC]oral2022
222K Part D

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Mycovia Pharmaceuticals
3 programs
3
1
OteseconazolePhase 3Small Molecule1 trial
OteseconazolePhase 3Small Molecule1 trial
OteseconazolePhase 3Small Molecule1 trial
Active Trials
NCT03840616Completed219Est. Dec 2020
NCT03561701Completed425Est. Aug 2021
NCT03562156Completed438Est. Aug 2021
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
VaccinePhase 1/2Vaccine
GSK
GSKLONDON, United Kingdom
1 program
VaccinePHASE_1_2Vaccine1 trial
Active Trials
NCT06190509Active Not Recruiting251Est. Apr 2027
Scynexis
ScynexisJERSEY CITY, NJ
1 program
Fluconazole TabletPHASE_31 trial
Active Trials
NCT04029116Completed440Est. Nov 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
ScynexisFluconazole Tablet
Mycovia PharmaceuticalsOteseconazole
Mycovia PharmaceuticalsOteseconazole
Mycovia PharmaceuticalsOteseconazole
GSKVaccine

Clinical Trials (5)

Total enrollment: 1,773 patients across 5 trials

NCT04029116ScynexisFluconazole Tablet

Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Start: Oct 2019Est. completion: Nov 2021440 patients
Phase 3Completed
NCT03840616Mycovia PharmaceuticalsOteseconazole

Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections

Start: Mar 2019Est. completion: Dec 2020219 patients
Phase 3Completed
NCT03561701Mycovia PharmaceuticalsOteseconazole

A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Start: Aug 2018Est. completion: Aug 2021425 patients
Phase 3Completed
NCT03562156Mycovia PharmaceuticalsOteseconazole

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Start: Aug 2018Est. completion: Aug 2021438 patients
Phase 3Completed
NCT06190509GSKVaccine

Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study

Start: Dec 2023Est. completion: Apr 2027251 patients
Phase 1/2Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (60% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.